Summary of Study ST000442
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000341. The data can be accessed directly via it's Project DOI: 10.21228/M8989V This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Study ID | ST000442 |
| Study Title | Metabolomics Analysis of Triple Negative Breast Cancer (BCa) Cell Lines |
| Study Type | Metabolomics comparison of different breast cancer cell lines |
| Study Summary | We used untargeted metabolomic profiling to distinguish this form of BCa from estrogen receptor positive (ER+) subtypes (+/- HER2/neu) and determine that may explain why a commonly used chemotherapeutic, paclitaxel, is generally ineffective at eliciting long-term cytotoxic and/or cytostatic responses in cell line models of TNBC. This metabolomics study used broad spectrum 1H NMR to compare Luminal A (BT474, MCF-7) and triple-negative (MDA-MB-231, MDA-MB-468) BCa cell lines, to determine differences in the two subtypes as well as distinguish therapeutic treatment responses for identifying new targets for drug discovery. |
| Institute | University of North Carolina |
| Department | Discovery Sciences |
| Laboratory | Sumner Lab |
| Last Name | Sumner |
| First Name | Susan |
| Address | Eastern Regional Comprehensive Metabolomics Resource Core, UNC Nutrition Research Institute, 500 Laureate Way, Kannapolis, NC, 28081 |
| susan_sumner @unc.edu | |
| Phone | 704-250-5066 |
| Submit Date | 2016-08-02 |
| Num Groups | 4 |
| Total Subjects | 24 |
| Study Comments | 4 breast cancer cell lines, treated with paclitaxel compared to controls (3 replicates/line/condition) |
| Publications | J. Proteome Res., Article ASAP, DOI: 10.1021/acs.jproteome.6b00430 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | 1r |
| Analysis Type Detail | NMR |
| Release Date | 2016-12-22 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR000341 |
| Project DOI: | doi: 10.21228/M8989V |
| Project Title: | Metabolomics Analysis of Triple Negative Breast Cancer Cell Lines |
| Project Type: | Metabolomics Analysis |
| Project Summary: | To date there are no clinically approved targeted therapies for triple negative breast cancer (TNBC). In addition to the absence of estrogen, progesterone, and HER2/neu receptors, TNBCs possess characteristics that make them some of the most aggressive forms of breast cancer (BCa). In terms of epidemiology, breast cancers with the triple negative profile present at a higher prevalence in premenopausal women under the age of 40, usually with a BMI greater than 30, and have higher incidences of mutations in BRCA1 or BRCA2 genes. Additionally, several studies have shown a higher prevalence in African American women, demonstrating a health disparity. In spite of this knowledge and the fact that most people respond to initial chemotherapeutic treatment, lasting treatment modalities used for the cure and maintenance of other BCa subtypes generally fail to significantly increase disease-free survival or diminish the rates of recurrence within the first five years after initial detection of TNBC. Our ultimate goal is to identify novel biomarkers which may be leveraged for initiating prevention strategies in high risk populations, earlier detection, or targeted treatment of this disease. |
| Institute: | RTI International |
| Department: | Discovery Sciences |
| Laboratory: | STS/NIH Eastern Regional Comprehensive Metabolomics Resource Core (RTI RCMRC) |
| Last Name: | Delisha |
| First Name: | Stewart |
| Address: | 3040, East Cornwallis Road, Research Triangle Park, NC 27709 |
| Email: | dstewart@rti.org |
| Phone: | 919-541-7204 |
| Funding Source: | Internal IR&D (RTI International) and RCMRC |
| Publications: | J. Proteome Res., Article ASAP |
